References
1. van Eijkelenburg NKA, Rasche M, Ghazaly E, et al: Clofarabine,
high-dose cytarabine and liposomal daunorubicin in pediatric
relapsed/refractory acute myeloid leukemia: a phase IB study.
Haematologica 103:1484-1492, 2018
2. Sander A, Zimmermann M, Dworzak M, et al: Consequent and intensified
relapse therapy improved survival in pediatric AML: results of relapse
treatment in 379 patients of three consecutive AML-BFM trials. Leukemia
24:1422-8, 2010
3. Kaspers GJ, Zimmermann M, Reinhardt D, et al: Improved outcome in
pediatric relapsed acute myeloid leukemia: results of a randomized trial
on liposomal daunorubicin by the International BFM Study Group. J Clin
Oncol 31:599-607, 2013
4. Hunger SP, Raetz EA: How I treat relapsed acute lymphoblastic
leukemia in the pediatric population. Blood 136:1803-1812, 2020
5. Wei AH, Strickland SA, Jr., Hou JZ, et al: Venetoclax Combined With
Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid
Leukemia: Results From a Phase Ib/II Study. J Clin Oncol 37:1277-1284,
2019
6. DiNardo CD, Pratz KW, Letai A, et al: Safety and preliminary efficacy
of venetoclax with decitabine or azacitidine in elderly patients with
previously untreated acute myeloid leukaemia: a non-randomised,
open-label, phase 1b study. Lancet Oncol 19:216-228, 2018
7. Konopleva M, Pollyea DA, Potluri J, et al: Efficacy and Biological
Correlates of Response in a Phase II Study of Venetoclax Monotherapy in
Patients with Acute Myelogenous Leukemia. Cancer Discovery 6:1106-1117,
2016
8. Morsia E, McCullough K, Joshi M, et al: Venetoclax and
hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on
86 patients. American Journal of Hematology 95:1511-1521, 2020
9. DiNardo CD, Rausch CR, Benton C, et al: Clinical experience with the
BCL2-inhibitor venetoclax in combination therapy for relapsed and
refractory acute myeloid leukemia and related myeloid malignancies. Am J
Hematol 93:401-407, 2018
10. Aldoss I, Yang D, Aribi A, et al: Efficacy of the combination of
venetoclax and hypomethylating agents in relapsed/refractory acute
myeloid leukemia. Haematologica 103:e404-e407, 2018
11. Karol SE, Alexander TB, Budhraja A, et al: Venetoclax in combination
with cytarabine with or without idarubicin in children with relapsed or
refractory acute myeloid leukaemia: a phase 1, dose-escalation study.
Lancet Oncol 21:551-560, 2020
12. Pullarkat VA, Lacayo NJ, Jabbour E, et al: Venetoclax and Navitoclax
in Combination with Chemotherapy in Patients with Relapsed or Refractory
Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Cancer Discov
11:1440-1453, 2021
13. Gibson A, Trabal A, McCall D, et al: Venetoclax for Children and
Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic
Lymphoma. Cancers (Basel) 14, 2021
14. Trabal A, Gibson A, McCall D, et al: Venetoclax for Acute Myeloid
Leukemia in Pediatric Patients: A Texas Medical Center Collaboration.
Blood 138:1247-1247, 2021
15. Winters AC, Maloney KW, Treece AL, et al: Single-center pediatric
experience with venetoclax and azacitidine as treatment for
myelodysplastic syndrome and acute myeloid leukemia. Pediatric Blood &
Cancer 67:e28398, 2020
16. Kline CN, Joseph NM, Grenert JP, et al: Targeted next-generation
sequencing of pediatric neuro-oncology patients improves diagnosis,
identifies pathogenic germline mutations, and directs targeted therapy.
Neuro-oncology 19:699-709, 2017
17. Agarwal SK, Salem AH, Danilov AV, et al: Effect of ketoconazole, a
strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2
inhibitor, in patients with non-Hodgkin lymphoma. Br J Clin Pharmacol
83:846-854, 2017
18. Rausch CR, DiNardo CD, Maiti A, et al: Venetoclax Dosing in
Combination with Antifungal Agents: Real World Experience in Patients
with Acute Myeloid Leukemia. Blood 134:2640-2640, 2019
19. Myers KC, Furutani E, Weller E, et al: Clinical features and
outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic
syndrome or acute myeloid leukaemia: a multicentre, retrospective,
cohort study. Lancet Haematol 7:e238-e246, 2020
20. Smith JL, Ries RE, Hylkema T, et al: Comprehensive Transcriptome
Profiling of Cryptic CBFA2T3–GLIS2 Fusion–Positive AML Defines Novel
Therapeutic Options: A COG and TARGET Pediatric AML Study. Clinical
Cancer Research 26:726-737, 2020
21. Smith SM, Lee A, Tong S, et al: Detection of a GLIS3 fusion in an
infant with AML refractory to chemotherapy. Cold Spring Harb Mol Case
Stud 8, 2022